January, 1 (week 1)– December,31 (week 52) | January, 1 (week1)-March 21 (week 11) | May, 24 (week 21) November, 14 (week45) | November, 29 (week 48) – December, 31 (week52) | |
---|---|---|---|---|
(entire year) | (before first COVID-19 shutdown) | (after first restart of the program) | (after second restart of the program) | |
% (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | |
All invitation | -2.6 (-2.8; 2.5) | -10.2 (-10.5; -9.9) | 1.0 (0.8; 1.2) | 0.3 (-0.2; 0.8) |
Stratified by gender | ||||
Men | -3.0 (-3.3; -2.8) | -10.9 (11.3; -10.5) | 1.0 (0.7; 1.3) | -0.2 (-0.9; 0.5) |
Women | -2.2 (-2.4; -2.0) | -9.6 (-10.0; -9.1) | 1.0 (0.8; 1.4) | 0.8 (0.1; 1.5) |
Stratified by age | ||||
50–54 | -3.9 (-4.2; -3.6) | -7.8 (-8.3; -7.3) | -1.4 (-1.8; -1.1) | -4.4 (-6.5; -2.4) |
55–59 | -1.1 (-1.4; -0.7) | -8.5 (-9.3; -7.6) | -2.7 (-3.1; -2.4) | 15.0 (14.2; 15.9) |
60–64 | -0.8 (-1.2; -0.5) | 0.9 (0.2; 1.5) | -1.3 (-1.8; -0.9) | -7.1 (-8.1; -6.0) |
65–69 | -2.4 (-2.9; -2.0) | -6.0 (-6.9; -5.2) | -1.1 (-1.7; -0.5) | 1.9 (0.6; 3.2) |
70–74 | -0.9 (-1.3; -0.5) | -24.0 (-25.0; -23.3) | 19.9 (19.4; 20.5) | -16.2 (-17.4; -15.0) |
Stratified by screening history | ||||
Type 1 | -3.9 (-4.1; -3.6) | -11.5 (-12; -11.0) | 1.5 (1.2; 1.8) | -6.6 (-7.3; -5.8) |
Type 2 | -3.7 (-4.0; -3.4) | -7.2 (-7.7; -6.8) | -1.5 (-1.8; -1.2) | -6.2 (-7.8; -4.7) |
Type 3 | -3.1 (-4.2; -2.1) | -10.9 (-12.8; -9.1) | 1.6 (0.2; 3.1) | 2.3 (-0.3; 4.8) |
Type 4 | -0.1 (-0.3; 0.0) | -2.3 (-2.6; -2.0) | 0.7 (0.5; 0.9) | 0.6 (0.2; 1.0) |